search
All Posts By

Beth Newcomb

Gray Market Peptides: So Much Hype, So Little Data (Medscape)

By In the News

Medscape spoke to Pinchas Cohen about the popularity of peptide supplementation despite the lack of rigorous evidence supporting the practice. He noted that he has testified before the FDA multiple times as an expert on other drugs, including human growth hormone, but no one has asked him to present on MOTS-c so far. If they did, he would advise against FDA deregulation at this time and instead appeal for research funding and accelerated clinical trials, he added.

3 FDA-approved drugs tested in new longevity trial: Inside the clinical debate (MDLinx)

By In the News

MDLinx quoted Sean Curran regarding a non-USC study investigating how the drugs rapamycin, dapagliflozin, and semaglutide affect aging. “In non-human studies, medications have been used to extend longevity across organisms, from simple yeast cells to more complex mammals,” Curran said. “Although this is the question everyone wants the answer to, perhaps the more important question we should be asking is, ‘To what extent can a medication influence health across the lifespan, including in older adults?’ Maximizing the health, especially at older ages, is far more important than extending longevity.”

Fraud is rampant, but good hospice care exists. Here’s a guide to making the right choice (Los Angeles Times)

By In the News

Los Angeles Times quoted Susan Enguidanos in a column on hospice fraud. “The biggest complaint,” she said of consumer reviews of hospice organizations on Google and Yelp was that hospice staff didn’t show up as much as expected. “They said they would come,” Enguidanos said, paraphrasing a typical response, “and they just didn’t show up.” The column was widely republished, including in Yahoo, AOL, and MSN.